The unique alterations of hippocampus and cognitive impairment in chronic obstructive pulmonary disease

Respiratory Research

Guang-He Fei¹  Jing Li¹ 

[1] Pulmonary Department, First Affiliated Hospital of Anhui Medical University, Hefei, Anhui 230022, China

关键词: S100B;    Pulmonary function;    Hippocampus;    Cognitive impairment;    Chronic obstructive pulmonary disease;   

Others  :  792181
DOI  :  10.1186/1465-9921-14-140

 received in 2013-10-09, accepted in 2013-12-13,  发布年份 2013

【 摘 要 】

Background

Cognitive impairment has been found in chronic obstructive pulmonary disease (COPD) patients. However, the structural alteration of the brain and underlying mechanisms are poorly understood.

Methods

Thirty-seven mild-to-moderate COPD patients, forty-eight severe COPD patients, and thirty-one control subjects were recruited for cognitive test and neuroimaging studies. Serum levels of S100B,pulmonary function and arterial blood gas levels were also evaluated in each subject.

Results

The hippocampal volume was significantly smaller in COPD patients compared to the control group. It is positively correlated with a mini mental state examination (MMSE) score, SaO₂ in mild-to-moderate COPD patients, the levels of PaO₂ in both mild-to-moderate and severe COPD patients. Higher S100B concentrations were observed in mild-to-moderate COPD patients, while the highest S100B level was found in severe COPD patients when compared to the control subjects. S100B levels are negatively associated with MMSE in both mild-to-moderate and severe COPD patients and also negatively associated with the hippocampal volume in the total COPD patients.

Conclusions

Hippocampal atrophy based on quantitative assessment by magnetic resonance imaging does occur in COPD patients, which may be associated with cognitive dysfunction and the most prevalent mechanism accountable for hippocampal atrophy is chronic hypoxemia in COPD. Higher serum S100B levels may be peripheral biochemical marker for cognitive impairment in COPD.

【 授权许可】

   
2013 Li and Fei; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Grant I, Heaton RK, McSweeny AJ, Adams KM, Timms RM: Neuropsychologic findings in hypoxemic chronic obstructive pulmonary disease. Arch Intern Med 1982, 142:1470-1476.
• [2]van Eeden SF, Sin DD: Chronic obstructive pulmonary disease: a chronic systemic inflammatory disease. Respiration 2008, 75:224-238.
• [3]Barnes PJ, Celli BR: Systemic manifestations and comorbidities of COPD. Eur Respir J 2009, 33:1165-1185.
• [4]Cazzola M, Bettoncelli G, Sessa E, Cricelli C, Biscione G: Prevalence of comorbidities in patients with chronic obstructive pulmonary disease. Respiration 2010, 80:112-119.
• [5]Antonelli Incalzi R, Marra C, Giordano A, Calcagni ML, Cappa A, Basso S, Pagliari G, Fuso L: Cognitive impairment in chronic obstructive pulmonary disease-a neuropsychological and spect study. J Neurol 2003, 250:325-332.
• [6]Kirkil G, Tug T, Ozel E, Bulut S, Tekatas A, Muz MH: The evaluation of cognitive functions with P300 test for chronic obstructive pulmonary disease patients in attack and stable period. Clin Neurol Neurosurg 2007, 109:553-560.
• [7]Hung WW, Wisnivesky JP, Siu AL, Ross JS: Cognitive decline among patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009, 180:134-137.
• [8]Dodd JW, Getov SV, Jones PW: Cognitive function in COPD. Eur Respir J 2010, 35:913-922.
• [9]Li J, Huang Y, Fei GH: The evaluation of cognitive impairment and relevant factors in patients with chronic obstructive pulmonary disease. Respiration 2013, 85:98-105.
• [10]Dawe RJ, Bennett DA, Schneider JA, Arfanakis K: Neuropathologic correlates of hippocampal atrophy in the elderly: a clinical, pathologic, postmortem MRI study. PLoS One 2011, 6:e26286.
• [11]Zhang J, Yu C, Jiang G, Liu W, Tong L: 3D texture analysis on MRI images of Alzheimer's disease. Brain Imaging Behav 2012, 6:61-69.
• [12]Apostolova LG, Green AE, Babakchanian S, Hwang KS, Chou YY, Toga AW, Thompson PM: Hippocampal atrophy and ventricular enlargement in normal aging, mild cognitive impairment (MCI), and Alzheimer Disease. Alzheimer Dis Assoc Disord 2012, 26:17-27.
• [13]Apostolova LG, Morra JH, Green AE, Hwang KS, Avedissian C, Woo E, Cummings JL, Toga AW, Jack CR Jr, Weiner MW, Thompson PM: Automated 3D mapping of baseline and 12-month associations between three verbal memory measures and hippocampal atrophy in 490 ADNI subjects. Neuroimage 2010, 51:488-499.
• [14]Sen J, Belli A: S100B in neuropathologic states: the CRP of the brain? J Neurosci Res 2007, 85:1373-1380.
• [15]Winocur G, Roder J, Lobaugh N: Learning and memory in S100-beta transgenic mice: an analysis of impaired and preserved function. Neurobiol Learn Mem 2001, 75:230-243.
• [16]Sheng JG, Mrak RE, Griffin WS: S100 beta protein expression in Alzheimer disease: potential role in the pathogenesis of neuritic plaques. J Neurosci Res 1994, 39:398-404.
• [17]Van Eldik LJ, Griffin WS: S100 beta expression in Alzheimer's disease: relation to neuropathology in brain regions. Biochim Biophys Acta 1994, 1223:98-403.
• [18]Li Y, Wang J, Sheng JG, Liu L, Barger SW, Jones RA, Van Eldik LJ, Mrak RE, Griffin WS: S100 beta increases levels of beta-amyloid precursor protein and its encoding mRNA in rat neuronal cultures. J Neurochem 1998, 71:1421-1428.
• [19]Pedersen A, Diedrich M, Kaestner F, Koelkebeck K, Ohrmann P, Ponath G, Kipp F, Abel S, Siegmund A, Suslow T, von Eiff C, Arolt V, Rothermundt M: Memory impairment correlates with increased S100B serum concentrations in patients with chronic schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2008, 3:1789-1792.
• [20]Chaves ML, Camozzato AL, Ferreira ED, Piazenski I, Kochhann R, Dall'Igna O, Mazzini GS, Souza DO, Portela LV: Serum levels of S100B and NSE proteins in Alzheimer's disease patients. J Neuroinflammation 2010, 7:6. Doi: 10.1186/1742-2094-7-6 BioMed Central Full Text
• [21]Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2011 guidelines http://www.csrd.org.cn/ppt/upload/201268164.pdf webcite
• [22]Watson C, Andermann F, Gloor P, Jones-Gotman M, Peters T, Evans A, Olivier A, Melanson D, Leroux G: Anatomic basis of amygdaloid and hippocampal volume measurement by magnetic resonance imaging. Neurology 1992, 42:1743-1750.
• [23]Bartko JJ, Carpenter WT Jr: On the methods and theory of reliability. J Nerv Ment Dis 1976, 163:307-317.
• [24]Jack CR Jr, Twomey CK, Zinsmeister AR, Sharbrough FW, Petersen RC, Cascino GD: Anterior temporal lobes and hippocampal formations: normative volumetric measurements from MR images in young adults. Radiology 1989, 172:549-554.
• [25]Csernansky JG, Wang L, Swank J, Miller JP, Gado M, McKeel D: Preclinical detection of Alzheimer's disease: hippocampal shape and volume predict dementia onset in the elderly. Neuroimage 2005, 25:783-792.
• [26]Mosconi L, Brys M, Glodzik-Sobanska L, De Santi S, Rusinek H, de Leon MJ: Early detection of Alzheimer's disease using neuroimaging. Exp Gerontol 2007, 42:129-138.
• [27]Arlt S, Buchert R, Spies L, Eichenlaub M, Lehmbeck JT, Jahn H: Association between fully automated MRI-based volumetry of different brain regions and neuropsychological test performance in patients with amnestic mild cognitive impairment and Alzheimer's disease. Eur Arch Psychiatry Clin Neurosci 2013, 263:335-344.
• [28]Daulatzai MA: Early stages of pathogenesis in memory impairment during normal senescence and Alzheimer's disease. J Alzheimers Dis 2010, 20:355-367.
• [29]Daulatzai MA: Quintessential risk factors: their role in promoting cognitive dysfunction and Alzheimer's disease. Neurochem Res 2012, 37:2627-2658.
• [30]Canessa N, Castronovo V, Cappa SF, Aloia MS, Marelli S, Falini A, Alemanno F, Ferini-Strambi L: Obstructive sleep apnea: brain structural changes and neurocognitive function before and after treatment. Am J Respir Crit Care Med 2011, 183:1419-1426.
• [31]Delacourte A, David JP, Sergeant N, Buée L, Wattez A, Vermersch P, Ghozali F, Fallet-Bianco C, Pasquier F, Lebert F, Petit H, Di Menza C: The biochemical pathway of neurofibrillary degeneration in aging and Alzheimer's disease. Neurology 1999, 52:1158-1165.
• [32]Van Eldik LJ, Wainwright MS: The Janus face of glial-derived S100B: beneficial and detrimental functions in the brain. Restor Neurol Neurosci 2003, 21:97-108.
• [33]Braga CW, Martinez D, Wofchuk S, Portela LV, Souza DO: S100B and NSE serum levels in obstructive sleep apnea syndrome. Sleep Med 2006, 7:431-435.